Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

SMS Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 10:48 am

Market Cap 1,684 Cr.
Current Price 199
High / Low 398/158
Stock P/E26.4
Book Value 70.6
Dividend Yield0.20 %
ROCE11.2 %
ROE9.27 %
Face Value 1.00
PEG Ratio30.22

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for SMS Pharmaceuticals Ltd

Competitors of SMS Pharmaceuticals Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of SMS Pharmaceuticals Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 1216164159149149135167161246164197173
Expenses 946565146131126109139133212131165140
Operating Profit 27-4-014182327282933333233
OPM % 22%-7%-1%9%12%16%20%17%18%14%20%16%19%
Other Income 2011211112112
Interest 5455666666554
Depreciation 8888888888899
Profit before tax 17-16-12161113151622222023
Tax % 37%-156%-21%12%22%24%29%21%26%26%25%28%24%
Net Profit 119-101589121216161417
EPS in Rs 1.241.07-1.160.090.590.951.101.421.441.881.931.682.03

Last Updated: February 28, 2025, 5:03 pm

Below is a detailed analysis of the quarterly data for SMS Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹173.00 Cr.. The value appears to be declining and may need further review. It has decreased from 197.00 Cr. (Sep 2024) to ₹173.00 Cr., marking a decrease of 24.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹140.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 165.00 Cr. (Sep 2024) to ₹140.00 Cr., marking a decrease of 25.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹33.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Sep 2024) to ₹33.00 Cr., marking an increase of ₹1.00 Cr..
  • For OPM %, as of Dec 2024, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Sep 2024) to 19.00%, marking an increase of 3.00%.
  • For Other Income, as of Dec 2024, the value is ₹2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Sep 2024) to ₹2.00 Cr., marking an increase of ₹1.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Sep 2024) to ₹4.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹9.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 9.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹23.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Sep 2024) to ₹23.00 Cr., marking an increase of ₹3.00 Cr..
  • For Tax %, as of Dec 2024, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2024) to 24.00%, marking a decrease of 4.00%.
  • For Net Profit, as of Dec 2024, the value is ₹17.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Sep 2024) to ₹17.00 Cr., marking an increase of ₹3.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 2.03. The value appears strong and on an upward trend. It has increased from ₹1.68 (Sep 2024) to 2.03, marking an increase of ₹0.35.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 6:48 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 248518587611438463465412563520522709780
Expenses 284461500522363369375332442405467592648
Operating Profit -365786897593908012111555117132
OPM % -14%11%15%15%17%20%19%19%22%22%10%16%17%
Other Income 1042164123535546
Interest 24141817161512121119222419
Depreciation 14131719192019222232323234
Profit before tax 3032675642606251916966686
Tax % 15%36%48%26%14%33%34%36%33%1%26%25%
Net Profit 2520354236404133616844964
EPS in Rs 2.532.404.154.924.204.784.893.867.208.030.485.837.52
Dividend Payout % 8%8%5%4%5%5%5%6%4%4%62%7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-20.00%75.00%20.00%-14.29%11.11%2.50%-19.51%84.85%11.48%-94.12%1125.00%
Change in YoY Net Profit Growth (%)0.00%95.00%-55.00%-34.29%25.40%-8.61%-22.01%104.36%-73.37%-105.59%1219.12%

SMS Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:3%
5 Years:9%
3 Years:8%
TTM:27%
Compounded Profit Growth
10 Years:9%
5 Years:4%
3 Years:-7%
TTM:53%
Stock Price CAGR
10 Years:16%
5 Years:45%
3 Years:25%
1 Year:6%
Return on Equity
10 Years:11%
5 Years:10%
3 Years:8%
Last Year:9%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 2:44 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 10888888888888
Reserves 234213246286254293331359420485487562589
Borrowings 149167167204149146144157255263254281285
Other Liabilities 79120119158897293103147126165217286
Total Liabilities 4715095406565015195776278308839141,0681,169
Fixed Assets 147247277370290279281280457438412437426
CWIP 96392913881842711333094
Investments 2661321374545454545454545
Other Assets 203217221252166187232259321389424556603
Total Assets 4715095406565015195776278308839141,0681,169

Below is a detailed analysis of the balance sheet data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹8.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹589.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹562.00 Cr. (Mar 2024) to ₹589.00 Cr., marking an increase of 27.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹285.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹281.00 Cr. (Mar 2024) to ₹285.00 Cr., marking an increase of 4.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹286.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹217.00 Cr. (Mar 2024) to ₹286.00 Cr., marking an increase of 69.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹1,169.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,068.00 Cr. (Mar 2024) to ₹1,169.00 Cr., marking an increase of 101.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹426.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹437.00 Cr. (Mar 2024) to ₹426.00 Cr., marking a decrease of 11.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹94.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹30.00 Cr. (Mar 2024) to ₹94.00 Cr., marking an increase of 64.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹45.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹603.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹556.00 Cr. (Mar 2024) to ₹603.00 Cr., marking an increase of 47.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹1,169.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,068.00 Cr. (Mar 2024) to ₹1,169.00 Cr., marking an increase of 101.00 Cr..

Notably, the Reserves (₹589.00 Cr.) exceed the Borrowings (285.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +-336559617332504090452250
Cash from Investing Activity +99-37-55-79-39-17-35-43-152-27-30-52
Cash from Financing Activity +-59-30-1027-33-15-13-292-12-3231
Net Cash Flow7-2-69102-5316-3929

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-185.00-110.00-81.00-115.00-74.00-53.00-54.00-77.00-134.00-148.00-199.00-164.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days52393736181920436834104122
Inventory Days1929081106114135170191148333243201
Days Payable83595879824959667097123130
Cash Conversion Cycle16170616350105131169146270224192
Working Capital Days126656263487395111115172196167
ROCE %-12%12%21%16%13%18%16%13%17%12%4%11%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters67.29%64.17%64.17%64.17%64.29%64.32%64.32%64.32%64.67%64.67%64.67%64.67%
FIIs0.61%0.63%0.59%0.59%0.59%0.67%0.60%0.59%0.17%0.18%0.52%0.31%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%1.98%2.13%2.55%2.55%
Public32.10%35.20%35.23%35.23%35.12%35.01%35.07%35.10%33.18%33.03%32.27%32.47%
No. of Shareholders27,51626,63826,49126,52625,53724,65325,24625,34130,14031,78033,13634,973

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF2790.0402792025-03-060%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 5.89-0.837.357.393.73
Diluted EPS (Rs.) 5.89-0.837.357.393.73
Cash EPS (Rs.) 9.544.2511.829.836.47
Book Value[Excl.RevalReserv]/Share (Rs.) 63.3654.4055.5648.5041.14
Book Value[Incl.RevalReserv]/Share (Rs.) 63.3654.4055.5648.5041.14
Revenue From Operations / Share (Rs.) 83.7961.6761.4166.5348.66
PBDIT / Share (Rs.) 14.307.0214.1214.7110.05
PBIT / Share (Rs.) 10.583.2210.3212.087.44
PBT / Share (Rs.) 7.810.638.0910.766.00
Net Profit / Share (Rs.) 5.810.458.027.203.86
NP After MI And SOA / Share (Rs.) 5.89-0.837.357.393.73
PBDIT Margin (%) 17.0711.3722.9922.1120.64
PBIT Margin (%) 12.625.2216.8018.1615.28
PBT Margin (%) 9.321.0213.1716.1712.32
Net Profit Margin (%) 6.930.7413.0510.827.93
NP After MI And SOA Margin (%) 7.02-1.3511.9611.107.66
Return on Networth / Equity (%) 9.29-1.5313.2315.239.06
Return on Capital Employeed (%) 12.754.3613.1716.5413.60
Return On Assets (%) 4.81-0.807.237.695.19
Long Term Debt / Equity (X) 0.220.260.310.360.19
Total Debt / Equity (X) 0.520.540.550.530.37
Asset Turnover Ratio (%) 0.740.600.610.780.69
Current Ratio (X) 1.621.611.921.591.51
Quick Ratio (X) 0.910.730.640.880.61
Inventory Turnover Ratio (X) 1.861.261.992.351.95
Dividend Payout Ratio (NP) (%) 5.09-35.974.080.0016.16
Dividend Payout Ratio (CP) (%) 3.1210.132.690.009.51
Earning Retention Ratio (%) 94.91135.9795.920.0083.84
Cash Earning Retention Ratio (%) 96.8889.8797.310.0090.49
Interest Coverage Ratio (X) 5.162.716.3311.166.96
Interest Coverage Ratio (Post Tax) (X) 3.101.184.606.463.68
Enterprise Value (Cr.) 1748.52734.331007.491231.25345.32
EV / Net Operating Revenue (X) 2.471.411.942.190.83
EV / EBITDA (X) 14.4412.368.439.884.06
MarketCap / Net Operating Revenue (X) 2.130.931.531.870.54
Retention Ratios (%) 94.90135.9795.910.0083.83
Price / BV (X) 2.811.061.692.570.64
Price / Net Operating Revenue (X) 2.130.931.531.870.54
EarningsYield 0.03-0.010.070.050.13

After reviewing the key financial ratios for SMS Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 5.89. This value is within the healthy range. It has increased from -0.83 (Mar 23) to 5.89, marking an increase of 6.72.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 5.89. This value is within the healthy range. It has increased from -0.83 (Mar 23) to 5.89, marking an increase of 6.72.
  • For Cash EPS (Rs.), as of Mar 24, the value is 9.54. This value is within the healthy range. It has increased from 4.25 (Mar 23) to 9.54, marking an increase of 5.29.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 63.36. It has increased from 54.40 (Mar 23) to 63.36, marking an increase of 8.96.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 63.36. It has increased from 54.40 (Mar 23) to 63.36, marking an increase of 8.96.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 83.79. It has increased from 61.67 (Mar 23) to 83.79, marking an increase of 22.12.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 14.30. This value is within the healthy range. It has increased from 7.02 (Mar 23) to 14.30, marking an increase of 7.28.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 10.58. This value is within the healthy range. It has increased from 3.22 (Mar 23) to 10.58, marking an increase of 7.36.
  • For PBT / Share (Rs.), as of Mar 24, the value is 7.81. This value is within the healthy range. It has increased from 0.63 (Mar 23) to 7.81, marking an increase of 7.18.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 5.81. This value is within the healthy range. It has increased from 0.45 (Mar 23) to 5.81, marking an increase of 5.36.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 5.89. This value is within the healthy range. It has increased from -0.83 (Mar 23) to 5.89, marking an increase of 6.72.
  • For PBDIT Margin (%), as of Mar 24, the value is 17.07. This value is within the healthy range. It has increased from 11.37 (Mar 23) to 17.07, marking an increase of 5.70.
  • For PBIT Margin (%), as of Mar 24, the value is 12.62. This value is within the healthy range. It has increased from 5.22 (Mar 23) to 12.62, marking an increase of 7.40.
  • For PBT Margin (%), as of Mar 24, the value is 9.32. This value is below the healthy minimum of 10. It has increased from 1.02 (Mar 23) to 9.32, marking an increase of 8.30.
  • For Net Profit Margin (%), as of Mar 24, the value is 6.93. This value is within the healthy range. It has increased from 0.74 (Mar 23) to 6.93, marking an increase of 6.19.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 7.02. This value is below the healthy minimum of 8. It has increased from -1.35 (Mar 23) to 7.02, marking an increase of 8.37.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 9.29. This value is below the healthy minimum of 15. It has increased from -1.53 (Mar 23) to 9.29, marking an increase of 10.82.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 12.75. This value is within the healthy range. It has increased from 4.36 (Mar 23) to 12.75, marking an increase of 8.39.
  • For Return On Assets (%), as of Mar 24, the value is 4.81. This value is below the healthy minimum of 5. It has increased from -0.80 (Mar 23) to 4.81, marking an increase of 5.61.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.22. This value is within the healthy range. It has decreased from 0.26 (Mar 23) to 0.22, marking a decrease of 0.04.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.52. This value is within the healthy range. It has decreased from 0.54 (Mar 23) to 0.52, marking a decrease of 0.02.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.74. It has increased from 0.60 (Mar 23) to 0.74, marking an increase of 0.14.
  • For Current Ratio (X), as of Mar 24, the value is 1.62. This value is within the healthy range. It has increased from 1.61 (Mar 23) to 1.62, marking an increase of 0.01.
  • For Quick Ratio (X), as of Mar 24, the value is 0.91. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 23) to 0.91, marking an increase of 0.18.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.86. This value is below the healthy minimum of 4. It has increased from 1.26 (Mar 23) to 1.86, marking an increase of 0.60.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 5.09. This value is below the healthy minimum of 20. It has increased from -35.97 (Mar 23) to 5.09, marking an increase of 41.06.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 3.12. This value is below the healthy minimum of 20. It has decreased from 10.13 (Mar 23) to 3.12, marking a decrease of 7.01.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 94.91. This value exceeds the healthy maximum of 70. It has decreased from 135.97 (Mar 23) to 94.91, marking a decrease of 41.06.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 96.88. This value exceeds the healthy maximum of 70. It has increased from 89.87 (Mar 23) to 96.88, marking an increase of 7.01.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 5.16. This value is within the healthy range. It has increased from 2.71 (Mar 23) to 5.16, marking an increase of 2.45.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 3.10. This value is within the healthy range. It has increased from 1.18 (Mar 23) to 3.10, marking an increase of 1.92.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 1,748.52. It has increased from 734.33 (Mar 23) to 1,748.52, marking an increase of 1,014.19.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.47. This value is within the healthy range. It has increased from 1.41 (Mar 23) to 2.47, marking an increase of 1.06.
  • For EV / EBITDA (X), as of Mar 24, the value is 14.44. This value is within the healthy range. It has increased from 12.36 (Mar 23) to 14.44, marking an increase of 2.08.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.13. This value is within the healthy range. It has increased from 0.93 (Mar 23) to 2.13, marking an increase of 1.20.
  • For Retention Ratios (%), as of Mar 24, the value is 94.90. This value exceeds the healthy maximum of 70. It has decreased from 135.97 (Mar 23) to 94.90, marking a decrease of 41.07.
  • For Price / BV (X), as of Mar 24, the value is 2.81. This value is within the healthy range. It has increased from 1.06 (Mar 23) to 2.81, marking an increase of 1.75.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.13. This value is within the healthy range. It has increased from 0.93 (Mar 23) to 2.13, marking an increase of 1.20.
  • For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 23) to 0.03, marking an increase of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of SMS Pharmaceuticals Ltd as of March 12, 2025 is: ₹138.50

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, SMS Pharmaceuticals Ltd is Overvalued by 30.40% compared to the current share price 199.00

Intrinsic Value of SMS Pharmaceuticals Ltd as of March 12, 2025 is: 139.71

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, SMS Pharmaceuticals Ltd is Overvalued by 29.79% compared to the current share price 199.00

Last 5 Year EPS CAGR: 0.87%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (366.08 cr) compared to borrowings (201.62 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (525.85 cr) and profit (55.23 cr) over the years.
  1. The stock has a low average ROCE of 11.75%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 107.75, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 136.83, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in SMS Pharmaceuticals Ltd:
    1. Net Profit Margin: 6.93%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.75% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 9.29% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 3.1
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.91
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 26.4 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.52
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

SMS Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 14/12/1987 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1987PLC008066 and registration number is 008066. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 709.26 Cr. and Equity Capital is Rs. 8.47 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No. 72, H.No. 8-2-334 / 3 & 4, Road No. 5, Opp. SBI Executive Enclave, Hyderabad Telangana 500034info@smspharma.com
http://www.smspharma.com
Management
NamePosition Held
Mr. Ramesh Babu PotluriChairman & Managing Director
Mr. Vamsi Krishna PotluriExecutive Director
Mr. Sarath Kumar PakalapatiIndependent Director
Mr. Sharvan KudaravalliIndependent Director
Mr. Sarvepalli SrinivasIndependent Director
Dr.(Mrs.) Neelaveni ThummalaIndependent Director

FAQ

What is the latest intrinsic value of SMS Pharmaceuticals Ltd?

The latest intrinsic value of SMS Pharmaceuticals Ltd as on 12 March 2025 is ₹138.50, which is 30.40% lower than the current market price of 199.00, indicating the stock is overvalued by 30.40%. The intrinsic value of SMS Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹1,684 Cr. and recorded a high/low of ₹398/158 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹589 Cr and total liabilities of ₹1,169 Cr.

What is the Market Cap of SMS Pharmaceuticals Ltd?

The Market Cap of SMS Pharmaceuticals Ltd is 1,684 Cr..

What is the current Stock Price of SMS Pharmaceuticals Ltd as on 12 March 2025?

The current stock price of SMS Pharmaceuticals Ltd as on 12 March 2025 is ₹199.

What is the High / Low of SMS Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of SMS Pharmaceuticals Ltd stocks is ₹398/158.

What is the Stock P/E of SMS Pharmaceuticals Ltd?

The Stock P/E of SMS Pharmaceuticals Ltd is 26.4.

What is the Book Value of SMS Pharmaceuticals Ltd?

The Book Value of SMS Pharmaceuticals Ltd is 70.6.

What is the Dividend Yield of SMS Pharmaceuticals Ltd?

The Dividend Yield of SMS Pharmaceuticals Ltd is 0.20 %.

What is the ROCE of SMS Pharmaceuticals Ltd?

The ROCE of SMS Pharmaceuticals Ltd is 11.2 %.

What is the ROE of SMS Pharmaceuticals Ltd?

The ROE of SMS Pharmaceuticals Ltd is 9.27 %.

What is the Face Value of SMS Pharmaceuticals Ltd?

The Face Value of SMS Pharmaceuticals Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in SMS Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE